Phase 4 N=20 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
Ovarian Cancer · Uterine Cancer
Primary: Overall Complete Response Rate — 10; 10 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy
Hyperemesis Gravidarum · Nausea Gravidarum · Vomiting of Pregnancy
Primary: Time to Symptom Control — 72; 87 minutes
N/A N=49 Non-invasive Vagal Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients With Gastroparesis and Related Disorders
Chronic Unexplained Nausea and Vomiting · Gastroparesis
Primary: Average Daily Use of Rescue Medications for Exacerbation of Nausea/Vomiting. — 1.186; 0.551; 0.754; 0.447 medications/day
N/A N=300 Management of Nausea and Vomiting Chemotherapy-induced in Normandy
Cancer · Nausea · Vomiting
Primary: Number of Participants With Acute Nausea and Vomiting — 101 Participants
Phase 3 N=30 Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients
Advanced Cancer
Primary: Mean Nausea Scores — 1; 9 units on a scale
Phase 2 N=126 Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial
Gastroparesis
Primary: Number of Participants With Improvement in Nausea — 29; 25 participants — p=0.43
Phase 3 N=317 Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
Breast Carcinoma
Primary: Average Nausea Defined as the Average [ MAXIMUM ] Nausea Rating Across 15 Assessment Points at Cycle 1 and 16 Assessment Points at Cycle 2 (Comparing Prochlorperazine or…
Phase 2 N=30 Topical Capsaicin for Cyclical Vomiting
Cyclical Vomiting
Primary: Nausea Visual Analog Scale — 41; 61 mm
Phase 2 N=64 Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department
Nausea and Vomiting
Primary: Vomiting at 0 to 120 Min. — 1; 4 number of participants exp vomiting
N/A N=108 Defining Adolescent Nausea Through Brain Imaging and Neurostimulation Response
Functional Gastrointestinal Disorders
Primary: Nausea Severity Scale — 2.18; 2.45 units on a scale
N/A N=208 Clinical Use of Baxter Animated Retching Faces (BARF) Scale in Children
Postoperative Nausea and Vomiting
Primary: Number of Patients With Nausea, Emesis, Severe Nausea, Severe Emesis and Number Receiving Rescue Antiemetics in the Post-Anesthetic Care Unit (PACU) — 60; 13; 8; 2…
Phase 2 N=83 Acupressure and Relaxation for Nausea Control
Nausea
Primary: Five-day Nausea Diary — 2.0; 2.1; 2.1; 1.9 Units on scale — p=0.932
Phase 3 N=46 Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
Malignant Neoplasm · Nausea · Vomiting
Primary: Change in Nausea Numerical Rating Scale (NRS) Between Day 5 and Day 15 — -2.0; -2.3 score on a scale — p=0.98
N/A N=64 Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin
Colorectal Cancer · Nausea · Vomiting
Primary: Percentages of Participants by Gender Who Reported Nausea During the First Week of Chemotherapy — 64; 34; 100 percentage of participants — p=.05
N/A N=242 Alternative Approaches for Nausea Control
Nausea
Primary: Patient Report Nausea Diary — 3.87; 3.55; 3.52 units on a scale — p=.05
N/A N=80 Inhalation Intervention for Nausea in the Emergency Department
Nausea · Vomiting
Primary: Nausea Verbal Numerical Rating Scale (0-10) at 10 Minutes Post Intervention — 3; 6 VNRS
Phase 2 N=100 Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV)
Chemotherapy-induced Nausea and Vomiting
Primary: Acute and Delayed Chemotherapy-Induced Nausea. The Self-reported Instruments Are Documented After the Chemotherapy Sessions and Collected on Study Visits 1, 2, and 3…
N/A N=27,034 Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis
Postoperative Nausea and Vomiting
Primary: Adherence to PONV Guidelines — 666; 5260; 5863 Participants
Phase 4 N=180 Acupuncture Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean
Nausea · Vomiting · Satisfaction
Primary: Nausea — 44; 14; 22 Participants — p=< 0.00001
Phase 4 N=289 The Montefiore Metoclopramide Study
Nausea · Extrapyramidal Symptoms
Primary: Nausea Scale — 0; 0; 0; 0 units on a scale
N/A N=9 Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis
Patients With Gastroparesis Who Have Failed Standard Therapy
Primary: Improvement of Overall Symptoms Based on Likert Scale — 2 Participants
N/A N=160 Effect of Intraoperative Crystalloid Volume on Postoperative Vomiting
Postoperative Vomiting
Primary: Postoperative Vomiting — 11; 9; 66; 68 participants — p=0.05
Phase 3 N=280 The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy
Nausea and Vomiting of Pregnancy
Primary: Diclectin Versus Placebo for Treatment of Nausea and Vomiting of Pregnancy (NVP) as Measured by the Change in Pregnancy Unique-Quantification of Emesis (PUQE) Overall…
Phase 3 N=380 Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Hematopoietic/Lymphoid Cancer · Nausea and Vomiting · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Proportion of Patients With no Nausea — 73.8; 45.3; 42.4; 25.4 percentage of participants
N/A N=200 Accupressure of P6 to Reduce Nausea During Cesarean Section
Pregnancy Related · Cesarean Delivery · Nausea
Primary: Presence of Intraoperative Vomiting — 17; 17 Participants — p=.94
Phase 3 N=91 Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants
Chemotherapy-induced Nausea and Vomiting
Primary: Number of Participants With Complete Response — 13; 21; 33; 24 Participants
N/A N=180 Prevention of Postoperative Nausea and Vomiting (PONV) in Surgical Patients
Postoperative Nausea and Vomiting
Primary: Incidence of Postoperative Nausea and Vomiting — 34.4; 29.8; 12.5; 7 percentage of participants — p=>0.76
Phase 3 N=1,455 An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Chemotherapy-Induced Nausea and Vomiting
Primary: Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, at Cycle 1 — 76.9; 69.5 percentage of responders — p=0.001
N/A N=51 EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron
Nausea
Primary: Time to Nausea Reduction by 50% by Visual Analog Scale. — 4.3; 3.5 Minutes
Phase 2 N=41 Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy
Acute Myeloid Leukemia
Primary: Percentage of Participants With Incidence of Vomiting/Retching From Day 1 Through End of Day 5 — 26.3 percentage of particpants